With 366 million people expected to be affected by diabetes in 2030, the diabetic nephropathy market is expected to grow consistently. The market was worth
US$2,262.2 million in 2014 and, at a 5.6% CAGR during the period between 2014 and 2020, it is expected to reach US$3,145.9 million by 2020.
Rising Number of Diabetic Patients Worldwide to Fuel Diabetic Nephropathy Market
Diabetic nephropathy is a serious condition associated with the kidneys, where increased levels of protein, especially albumin, are present in urine. In a
patient affected with diabetic nephropathy, albumin in the urine increases to potentially fatal amounts. The increasing prevalence of diabetes has
primarily fueled the diabetic nephropathy market. According to the World Health Organization (WHO), about 9% adults aged above 18 years were affected by
diabetes worldwide in 2014. By 2030, the disease is expected to be the seventh leading cause of death worldwide. As diabetes is commonly associated with
obesity, the diabetic nephropathy market is estimated to grow along with the rising number of obese people across the globe. The increasing investment in
research and development of drugs to treat diabetic nephropathy will boost the overall market. Nowadays, there is increased awareness among people about
diabetes and kidney-related disorders. This will further help the market grow, particularly in previously unexplored regions.
However, the long duration of clinical trials, in conjunction with the strict regulatory requirements by authorities such as the European Medicines Agency
and the U.S. Food and Drug Administration will slow down the growth of the diabetic nephropathy market. Lack of comprehensive therapeutic management will
also affect the growth of the overall market. The increasing usage of combination therapy to treat the condition is gaining popularity and is expected to
be the key market trend during the forecast horizon.
Angiotensin-converting Enzyme (ACE) Inhibitors to be Key Disease Modifying Therapy
The diabetic nephropathy market has been segmented on the basis of the disease modifying therapy into angiotensin receptor blockers, angiotensin-converting
enzyme (ACE) inhibitors, calcium channel blockers, renin inhibitors, diuretics, antioxidant inflammation modulator, monocyte chemoattractant proteins
inhibitor, connective tissue growth factor inhibitors, G-protein coupled receptors, and endothelin-A receptor antagonist. As hypertension is usually a
consequence of diabetic nephropathy, use of antihypertensive agents is usually prescribed in the treatment. ACE inhibitors can reduce the level of
progression of the disease by a greater degree than other hypertensive agents and hence this segment is expected to grow significantly.
North America Leads Global Diabetic Nephropathy Market
Globally, the diabetic nephropathy market has been divided into Asia, North America, and Europe. North America has been leading the overall market,
followed by Europe. According to the American Diabetes Association, in the U.S. alone, around 40% of new cases of diabetic nephropathy have been reported
in the recent past. The U.S. and Canada will contribute significantly to the diabetic nephropathy market in North America. Asia is expected to be the
fastest growing region of the market during the forecast period, with rising number of patients in Japan, China, and India affected with the condition.
Key Players of the Diabetic Nephropathy Market
Some of the key players of the diabetic nephropathy market include Pfizer Inc., Novartis AG, Sanofi, and Bayer AG, among others.
Browse the full Global Diabetic Nephropathy Market report at http://www.mrrse.com/diabetic-nephropathy-market